Decreased serum level of sphingosine-1-phosphate: a novel predictor of clinical severity in COVID-19

Giovanni Marfia1,2,3,*,†‡, Stefania Navone1,3,†, Laura Guarnaccia1,4, Rolando Campanella1, Michele Mondoni5, Marco Locatelli1,3,6, Alessandra Barassi7, Laura Fontana6, Fabrizio Palumbo2, Emanuele Garzia2,8, Giuseppe Ciniglio Appiani2, Davide Chiumello9, Monica Miozzo6,10, Stefano Centanni5,† & Laura Riboni11,‡

Abstract

The severity of coronavirus disease 2019 (COVID-19) is a crucial problem in patient treatment and outcome. The aim of this study is to evaluate circulating level of sphingosine-1-phosphate (S1P) along with severity markers, in COVID-19 patients. One hundred eleven COVID-19 patients and forty-seven healthy subjects were included. The severity of COVID-19 was found significantly associated with anemia, lymphocytopenia, and significant increase of neutrophil-to-lymphocyte ratio, ferritin, fibrinogen, aminotransferases, lactate dehydrogenase (LDH), C-reactive protein (CRP), and D-dimer. Serum S1P level was inversely associated with COVID-19 severity, being significantly correlated with CRP, LDH, ferritin, and D-dimer. The decrease in S1P was strongly associated with the number of erythrocytes, the major source of plasma S1P, and both apolipoprotein M and albumin, the major transporters of blood S1P. Not last, S1P was found to be a relevant predictor of admission to an intensive care unit, and patient’s outcome. Circulating S1P emerged as negative biomarker of severity/mortality of COVID-19 patients. Restoring abnormal S1P levels to a normal range may have the potential to be a therapeutic target in patients with COVID-19.

Keywords Coronavirus; COVID-19; intensive care unit; prognostic biomarker; sphingosine-1-phosphate

Subject Categories Biomarkers; Microbiology, Virology & Host Pathogen Interaction

Introduction

In December 2019, a novel enveloped RNA betacoronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), rapidly spread from China throughout the globe, causing the pandemic respiratory disease COVID-19. Lombardy has been the most affected Italian region by the COVID-19 (Sotgiu et al, 2020) with > 175,000 cases, and 17,414 ascertained deaths (as of October 29, 2020, source: Italian Health Ministry).

The clinical spectrum of COVID-19 varies from asymptomatic/paucisymptomatic forms to critical conditions requiring support in an intensive care unit (ICU), and characterized by respiratory and multiple organ failure, systemic manifestations as septic shock, and even death (Guan et al, 2020; Gattinoni et al, 2020). The management of COVID-19 patients is constantly evolving, and so far, several medications are available, although without efficacy confirmation by clinical trials in most instances.

It is believed that the cytokine storm caused by systemic overproduction of pro-inflammatory cytokines, including interleukin-6 (IL-6), is a relevant cause of disease severity, progression, and death in COVID-19 patients (Song et al, 2020b). However, even though clinical features directly related to the rapid and intense inflammation, the lack of direct evidence makes unclear how the exuberant inflammatory process and organ failure is completed. Despite the importance of the older age and underlying comorbidities as prognostic factors associated with severity/death of COVID-19 patients, the evolution of SARS-CoV-2 infection is often very heterogeneous and unpredictable, and robust prognostic biomarkers, and potential therapeutic targets are still lacking. Thus, the actual, rapidly expanding knowledge on...
COVID-19 highlights the need for a better understanding of its pathophysiology, and for developing novel biomarkers with efficacious prognostic value, and potential therapeutic applications.

Among multiple mediators of inflammation, sphingosine-1-phosphate (S1P) emerged as a key signal (Obinata & Hla, 2019), involved in the regulation of multiple pathophysiological processes, including vascular physiology, and immunity (Yanagida & Hla, 2017; Bryan & Del Poeta, 2018). This bioactive sphingoid is produced intracellularly by sphingosine kinases, and, after extracellular release, it exerts pleiotropic effects through binding to specific G protein-coupled receptors (S1P1–5; Liu et al, 2012). In physiological conditions, S1P is present at high concentrations in blood, by the contribution of erythrocytes (Hänel et al, 2007), endothelial cells (Venkataraman et al, 2008), and platelets (Yatomi et al, 2000). To the opposite, its levels in other tissues are low, creating a vascular S1P gradient, crucial for S1P to exert its regulatory roles (Yanagida & Hla, 2017). In the systemic circulation, about 60% of plasma S1P is carried by high-density lipoproteins (HDL), bound to apolipoprotein M (apoM), and about 30% by albumin, and the biological properties of S1P attached to ApoM and albumin are different (Kurano & Yatomi, 2018). On these premises and taking into account that S1P is involved in viral infections (Wolf et al, 2019), and in sepsis (Winkler et al, 2019), the objective of this study was to determine the serum levels of S1P, and its transporters apoM and albumin, to evaluate their clinical importance as prognostic/predictive biomarkers in COVID-19.

Results

Characteristics of the study population

Demographic and clinical characteristics of the two groups are shown in Table EV1. HLT and COV groups were very similar for sex and age, as well as for hypertension or diabetes incidence. The HLT population presented all the biochemical parameters within the normal range, whereas COV patients exhibited a pattern of hematological and biochemical abnormalities. In particular, we found significant differences in RBC, HGB, HCT, RDW, WBC, neutrophils, lymphocytes, and monocytes values (Table EV2). Moreover, the calculated neutrophils-to-lymphocytes ratio (NLR) accounted for 1.78 (IQR: 1.47–2.09) in HLT subjects and 7.05 (IQR: 5.34–8.85) in COV patients, with a strong statistically significant difference ($P < 0.0001$) between the two groups.

Among the biochemical analytes, we found multiple statistically significant differences between COV and HLT (Table EV3), including significant decrease in total proteins, albumin, total cholesterol, HDL-C, 25-OH vitamin, and significant increase in fibrinogen, urea, ferritin, GGT, AST, ALT, CRP, LDH, NT-proBNP, and IL-6. Total bilirubin, albeit within the normal range, was significant lower in COV patients than in HLT. Furthermore, the coagulation profile was altered in COV patients with a significant increased level of D-dimer and fibrinogen. To the contrary, coagulation parameters PT and aPTT, and electrolytes, including calcium, sodium, potassium, and chloride were similar in HLT and COV cohorts.

ELISA assays provided a mean value of serum S1P concentration in the HLT group of 0.87 µM, which is very similar to that reported by a recent study on 174 healthy blood donors, and obtained by LC/MS/MS (Daum et al, 2020). The measurement of serum levels of S1P and its transporter apoM revealed a highly significant decrease in both molecules in COV patients, compared to HLT subjects (Fig 1A and B). In particular, the median S1P values were 0.87 and 0.69 µM (Fig 1A), and the median apoM values were 39.0 and 24.3 µg/ml (Fig 1B), in HLT and COV, respectively. These results suggest a systemic involvement of S1P/apoM complex in COVID-19. However, the Pearson correlation between S1P and apoM gave no statistical significance, even though a modest positive trend was present (Fig 1C). Interestingly, serum S1P levels significantly correlated with RBC, HGB, and HCT values (Fig 1D–F).

The Pearson correlation demonstrated a significant correlation between S1P and both HDL-C (Fig 2A), and albumin (Fig 2B). In parallel, significant correlations were found between apoM and HDL-C (Fig 2C) and albumin (Fig 2D). To the contrary, no significant correlation was found between PLT and S1P, as well as PLT and apoM.

Identification of disease’s severity markers

To investigate the role of S1P and apoM as circulating biomarkers in COVID-19 infection severity, we stratified patients based on whether or not they needed ICU admission, categorizing our COV patient cohort into ICU and noICU groups. As shown in Table EV4, both groups were homogeneous in terms of age and BMI. As expected, ICU patients showed a significant increase in mortality rate, even if their frequency of hypertension and diabetes was significantly lower than that of noICU. Furthermore, the comparison between blood and biochemical parameters revealed that ICU patients, compared to noICU, have a significant decrease in RBC, HGB, HCT, and lymphocytes, concomitant to a significant increase in WBC, neutrophils, NLR, urea, AST, ALT, LDH, CRP, and D-dimer (Table EV5). Intriguingly, patients admitted to ICU had significantly lower values of S1P, apoM, and of albumin and HDL-C, compared to the noICU group (Fig 3A–D), suggesting the potential role of S1P and its blood transporters apoM, albumin, and HDL-C, as circulating biomarkers of disease severity.

To determine the possible relation between serum levels of S1P and apoM and the severity of infection in COVID-19 patients, we used PSI, length of hospitalization, and NLR as parameters. Interestingly, a significant negative correlation was found between S1P and PSI, days from hospital admittance, and NLR (Fig 4A–C). Similarly, significant negative correlations were found between apoM, PSI, and NLR (Fig 4D and F), but not between apoM and days from hospital admission (Fig 4E).

In univariable logistic regression analysis, PSI, S1P, apoM, RBC, HGB, HCT, WBC, NLR, CRP, and albumin were significantly associated with ICU admission. Results of multivariable regression analysis showed that NLR and S1P are independent predictors for ICU admission. Noteworthy, S1P, among the considered parameters, is the most important risk factor for ICU admission for COVID-19 patient (OR: 39.45, [95% CI: 1.51–1031.60]; $P = 0.027$; Table EV6). Further, to estimate the potential prognostic role of S1P, COV patients were stratified by the cutoff value of S1P 0.60 µM, according to Youden index. Cox regression analysis revealed that S1P is a significant predictor of ICU admission, and in-hospital mortality (Fig 5A and B). Of relevance, the mortality
rate in COV patients with \( S1P < 0.60 \, \mu M \) (13.6%) was found significantly higher \( (P < 0.05) \) than that with \( S1P \geq 0.60 \, \mu M \) (4.5%). In addition and interestingly, patients admitted to ICU with low serum S1P showed a meaningful rise of mortality rate up to 33%.

**Discussion**

The major findings of this study are that serum S1P levels are significantly lower in COVID-19 patients than HLT and predict both ICU admission and in-hospital mortality. A very recent lipidomic study, published while our paper was in preparation, reported that S1P is significantly reduced in plasma samples of COVID-19, without indicating molar concentrations, which prevents comparison across independent studies, and without addressing to disease severity and patient outcome (Song et al., 2020a). To our knowledge, this is the first study providing evidence for serum S1P association with COVID-19 severity, and suggesting S1P as a novel circulating biomarker of COVID-19 severity and morbidity.

Previous studies demonstrated that the cytokine storm plays a key role in COVID-19, and the increase of pro-inflammatory cytokines is associated with disease severity (Song et al., 2020b). Of note, S1P was implicated in both upstream and downstream cytokine production and increased interstitial levels of S1P at the inflammatory sites induce the expression of pro-inflammatory cytokines (Obinata & Hla, 2019), suggesting that local, interstitial S1P may concur to the cytokine storm of COVID-19. Taking into consideration the relevance of the cytokine storm in COVID-19, we here discuss our findings on serum S1P in COVID-19 patients through two main sections: (i) the possible mechanisms underlying decreased level in serum S1P, including cellular contributors of circulating S1P, and its blood transporters; (ii) the functional consequences and clinical implications of low circulating S1P. To facilitate the reader, Fig 6 provides an overview of the proposed mechanisms underlying S1P involvement in COVID-19.

**Mechanisms underlying the reduction of serum S1P**

Due to their unique S1P metabolism and processing, erythrocytes are a major source of S1P in blood plasma, their count positively associates with plasma S1P levels (Hänel et al, 2007). We found that COVID-19 patients have a significantly reduced RBC count, and that this count, together with total hemoglobin and hematocrit values were directly correlated with serum S1P. These findings, and the reports on low blood S1P in anemic patients (Ohkawa et al, 2008), strongly suggest that RBC decrease may contribute to low serum S1P in COVID-19 patients. Although the mechanism-underlying anemia in COVID-19 is unknown, a possible
explanation resides in the finding that pro-inflammatory cytokines inhibit erythropoietin-induced erythropoiesis (Pierce & Larson, 2005). This process was associated with RDW increase (Pierce et al., 2005), which we found in our COVID-19 cohort. Furthermore, as a very recent preprint notice reported a significant sphingolipid decrease in RBC from COVID-19 patients (preprint: Thomas et al., 2020), we cannot exclude that a decrease in S1P synthesis/export by erythrocytes might also occur. In addition to erythrocytes, the vascular endothelium efficiently contributes to plasma S1P levels through the plasma membrane S1P-transporter Spns2 (Nagahashi et al., 2013). As pro-inflammatory cytokines down-regulate Spns2 in endothelial cells (Jeya Paul et al., 2020), and thus their S1P export, it is possible that the cytokine storm in COVID-19 patients contributes to an endothelial-induced S1P drop. In agreement, patients with sepsis have decreased serum S1P levels (Winkler et al., 2019).

A further source of blood S1P are platelets, which efficiently store S1P, and mainly release it into the circulation during clotting, leading to higher S1P levels in serum than plasma (Yatomi et al., 2000). Our COVID-19 cohort had platelet numbers and parameters in the normal range, most probably excluding platelets as responsible for their low serum S1P.

Besides possible alterations of S1P release into blood, our data reveal that decreased levels of apoM and albumin, the two major S1P transport proteins, are likely involved in circulating S1P reduction. Our study unraveled three principal findings regarding S1P

---

**Figure 2. Correlations between S1P/apoM and their transporters.**

A, B Correlations between S1P and HDL-C (A), and albumin (B).
C, D Correlations between apoM and HDL-C (C) and albumin (D).

Data information: Scatter plots and fitted regression line are shown in each figure. Each S1P and apoM measurement was run in triplicate, and performed at least twice in independent assays. Pearson correlation was performed for statistical analysis. Exact $P$ values or $P < 0.0001$ are reported.
carriers in COVID-19 patients. First, we found that serum apoM and albumin were both significantly lower in COVID-19 patients compared to HLT, and particularly in ICU than noICU patients. As these proteins, besides acting as S1P vehicle, are essential for S1P release from erythrocytes, and modulate blood S1P concentration (Christensen et al., 2017), their decrease most probably concurs to the drop of circulating S1P in COVID-19 patients. Of note, both apoM and albumin are considered negative acute-phase proteins (Feingold et al., 2008), as their levels profoundly decrease during inflammatory conditions. Here, we show that concomitant to albumin and apoM reduction, the serum levels of CRP and ferritin, widely recognized as positive acute-phase reactants that rise dramatically as part of the inflammatory response mediated by increased cytokines such as IL-6 (Streetz et al., 2001), significantly increased in COVID-19 patients. Thus, it appears reasonable that apoM and albumin drop as part of the inflammatory response mediated by the cytokine storm in COVID-19 patients.

A second interesting observation of our study is that serum values of S1P significantly correlate with HDL-C, and are lower in ICU than noICU patients, indicating that serum S1P levels are influenced by HDL, and are related to COVID-19 severity. This is in agreement with reports showing that: (i) plasma S1P levels positively correlate with plasma levels of HDL-C (Zhang et al., 2005), (ii) severe forms of sepsis result in severely decreased plasma levels of HDL-C, (iii) HDL-S1P relates to sepsis severity, and contributes most to the severe drop of total plasma S1P found in septic shock patients (Winkler et al., 2019).

Third, the serum levels of S1P, although related to HDL-C, did not significantly correlate with serum apoM levels, indicating that the low apoM levels in patients are probably not directly linked to their decreased S1P level. The reason of this discrepancy might be that S1P is linked also to albumin and other HDL–apolipoproteins, and that apoM can bind lipids other than S1P.

**Pathological consequences and clinical implications of reduced serum S1P**

Pathological key features of COVID-19 are complex, and its pathogenesis remains unclear.

Here, we report current evidence on the multiple effects of blood S1P, discussing them in the context of reduced serum S1P, together
with its clinical implication in COVID-19. In agreement with previous findings (Guan et al., 2020), we found that COVID-19 patients present lymphopenia. The mechanisms underlying lymphopenia remain unknown, and we hypothesize that the decrease in S1P levels might participate. Indeed, the S1P gradient between blood and tissues is essential for lymphocyte egress from lymphoid organs, which occurs via S1P1 (Baeyens & Schwab, 2020). In agreement, FTY720, a functional antagonist of the S1P/S1P1 signaling pathway approved as immunosuppressant, produces peripheral lymphopenia (Pelletier & Hafler, 2012). Of interest, the S1P1-mediated trafficking and egress of lymphocytes are limited to albumin-S1P, and not shared by apoM-S1P (Baeyens & Schwab, 2020). On these bases, our findings on the
Figure 6.
A further relevant physiological role of circulating S1P consists in its protective and anti-inflammatory actions on endothelial cells (Christoffersen et al., 2011). ApoM/S1P exerts more potent activities on endothelial cells than albumin/S1P, and particularly in limiting endothelial inflammation, and maintaining the endothelial barrier (Christoffersen et al., 2011). As described above, free interstitial S1P increases at inflammation sites, where, opposite to its plasma anti-inflammatory effects, it is involved in the propagation of inflammation. Considering the scavenger actions of apoM/HDL (Kurano & Yatomi, 2018), which are involved in inflammation resolution by neutralizing S1P excess at inflammation sites, the deficiency of apoM might contribute to exacerbate inflammation in COVID-19. Overall, despite we cannot exclude that the decreased levels of S1P could be an epiphenomenon of host tissue damage, based on its protective properties on endothelial barrier and anti-inflammatory properties of apoM/S1P, the decrease in S1P and apoM might explain the disturbed vascular barrier function, and organ injuries of COVID-19. In agreement, it was previously reported that, during septic challenge, the plasma levels of S1P drop to very low levels, the liver synthesis of apoM decreases severely and the plasma levels of apoM are reduced. Thus, the decrease in circulating S1P may contribute to the clinical severity of pathologies involving endothelial barrier dysfunction as sepsis (Winkler et al., 2019), peripheral artery disease (Soltan et al., 2016), and liver cirrhosis (Becker et al., 2017).

Further interesting findings of our study refer to the relation between S1P (and apoM) and the established inflammation marker NLR, as well as the clinical prediction tool PSI, both found correlated with COVID-19 severity (Ciccullo et al., 2020; Satici et al., 2020). We report here that both NLR and PSI were not only significantly higher in ICU than noICU group, but also correlated with serum S1P and apoM, and that S1P negatively correlates with the length of hospitalization. Furthermore, when COVID-19 patients were stratified using a cutoff for S1P, the patients with low serum level displayed significant increased probability of ICU admission and mortality rate. Overall, these correlations strongly suggest that circulating S1P levels may be clinically used as negative biomarkers to predict severity/mortality of COVID-19 patients.

Finally, our study suggests that restoring low S1P and its transporters to healthy range may be a therapeutic target for reducing COVID-19 severity, and death. Contrasting results were found on Fingolimod, an FDA-approved functional antagonist of S1P. Indeed, accordingly previous data reporting a potential role for Fingolimod to blunt cytokine storm induced by (Oldstone & Rosen, 2014) H1N1 and influenza virus (Walsh et al., 2011) infection, a clinical trial for Fingolimod administration in COVID-19 patients has been initiated and then discontinued in some patients for marked lymphopenia (www.clinicaltrial.gov NCT04280588). Furthermore, glucocorticoids, widely used in the treatment of COVID-19 with contra
dictory effects (Ledford, 2020), target S1P signaling, by inhibiting S1P-induced cytokine secretion (Che et al., 2014). Our findings strongly suggest that S1P circulating levels should be measured in COVID-19 patients before administration of any S1P-modulating drug, including glucocorticoids, and that therapeutic modalities (local/systemic) should be evaluated before treatment.

Our study has some limitations. First, it is a single-center study, with a relatively small sample size. This could have reduced the power of the study, but not the novel finding on the reduction of S1P and apoM in the serum of COVID-19 patients. Further multicenter studies with a larger patient cohort are needed to in-depth evaluate the here-described correlation of S1P levels with circulating parameters and disease severity of COVID-19. Second, as plasma S1P levels should be measured in samples collected under specific conditions, and platelets may leak S1P during blood storage, we used serum to measure S1P, with the consequent influence of platelet-derived S1P. Further studies are needed to elucidate the association between S1P and COVID-19 by using plasma, and by separating S1P bound to HDL from S1P bound to albumin. Third, we performed the evaluation of serum S1P by an ELISA assay, which may have pitfalls. Although our data were validated by an enzymatic method, and S1P levels in the control group were comparable with those reported by HPLC/MS/MS, an accurate quantification of serum S1P levels through this technique will strengthen future findings. Finally, we were unable to collect blood samples during hospitalization to measure S1P at different time points in the same patients. Answering these questions in future studies will help to determine whether S1P and/or apoM could be markers to facilitate the management of COVID-19 in clinical practice, and potential helpful targets for COVID-19 treatments.

In conclusion, the current study establishes the decrease in serum S1P and apoM as novel circulating biomarkers associated with COVID-19 severity and morbidity. We speculate that S1P may play a role in endothelial barrier dysfunction, altered immune response, and persistent excessive inflammation in COVID-19 patients. Understanding the mechanisms leading to decreased serum S1P in COVID-19, and its multi-systemic effects should be the focus of future work, to advance our knowledge of this disease. Finally, the present investigation suggests that restoring abnormal S1P levels to a normal range, and balancing its binding to albumin and apoM to healthy conditions, may have the potential to be a therapeutic target for reducing the risk of disease progression and death, and, not last, to mount an effective immune response after vaccination in patients with COVID-19.

Materials and Methods

Study population and clinical variables

This prospective, case–control study was approved by the Ethic Committee of Ospedale San Paolo in Milan, Lombardy, Italy (COST
Action n.2020/ST/057). Patients with confirmed positivity to SARS-CoV-2 by molecular test of nasopharyngeal swabs (COV, n = 111), were enrolled consecutively during hospitalization in March–May 2020 at Ospedale San Paolo, outbreak epicenter of the Italian pandemic cluster. Also, healthy subjects (HLT, n = 47) were tested. Informed consent was obtained from all human subjects, and the experiments were conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report. Blood sample collection was performed the day of the hospital admission. During hospitalization, a subgroup of these patients with severe symptoms were admitted to the Intensity Care Unit (ICU). In addition, Pneumonia Severity Index (PSI) was calculated at time of admission. Electronic data on demographics, medical history and comorbidities, illness onset and symptoms, vital signs, and baseline plasma/serum-based analytes were recorded for all admitted patients.

Measurement of serum S1P

For serum S1P and apoM measurements, an aliquot (5 ml) of whole blood was collected in covered vacutainer without anti-coagulant. Tubes were left at room temperature for 30–45 min, and then were centrifuged (2,000 g, 15 min). The obtained serum, inspected to assess limpidity, was carefully transferred into clean tubes, aliquoted, and stored at –80 °C until use, without repeated freeze-thaw cycles. The S1P levels were measured in duplicate, in at least two different serum aliquots from each patient, by enzyme-linked immunosorbent assay (ELISA) assay kit (Echelon Biosciences, Salt Lake City, USA), according to manufacturer’s instruction. The standard S1P curve ranged from 0.03 to 4 μM, and a semi-log analysis was used to interpole unknown samples. To assess ELISA specificity, different concentrations of exogenous S1P were added to HLT and COV sera. A sigmoidal curve, very similar in HLT and COV samples, was obtained, excluding serum interferences. The linearity of the serum measurement was initially checked on 4 samples at two different dilutions (1:5 and 1:10). Then, all samples were diluted 1:10 in delipidized serum, and known low and high S1P standards were run in parallel with experimental samples, as controls. Each S1P measurement was run in triplicate, and performed at least twice in independent assays. To validate ELISA assays, five serum samples from both controls and COVID-19 patients were submitted to double partitioning (first in alkaline, and then in acidic conditions), and S1P concentration in the final acidic organic phase was measured by an enzymatic assay as previously reported (Edsall et al, 2000), with minor modifications (Abdel Hadi et al, 2018). The results demonstrated very similar values with the two methods, the difference of the coefficient of variation (the ratio of the standard deviation over the mean of the measurements) being < 14% in both groups.

Measurement of serum apoM

ApoM levels were measured in serum (diluted 1:20,000) by the Human apoM ELISA®PRO kit (Mabtech, Inc., Cincinnati, USA). Samples with known low and high concentrations of apoM were tested together with the study participant samples. The range of apoM standard curve was 0.03–20 ng/ml, and the 4-parameter curve fit was used to interpole sample measurements. Each apoM measurement was run in triplicate, and performed at least twice in independent assays.

Statistical analyses

The calculation of power size was performed considering a power of 80%, a type I error rate of 5%, and an effect size of 50%. The continuous variables were expressed as median values and interquartile range (IQR). Discrete variables were reported as counts or percentages. Blood parameters were tested for normality using the Kolmogorov–Smirnov and Shapiro–Wilk tests, and when normally distributed, the two conditions were compared by the two-tailed Student’s t-test. The Pearson correlation test was used to assess the univariate association between variables.

The primary clinical endpoint of our study was ICU admission. The association of baseline characteristics and clinical findings with ICU admission was initially evaluated using univariable logistic regression. Variables with P < 0.05 were considered as potential risk factors and included in the multivariable logistic regression analysis with the backward stepwise method, in order to explore variables that were independently associated with ICU admission. The cutoff was calculated according to the maximum value of Youden index, and the hazard ratio for ICU admission and mortality was calculated using the Cox proportional hazard model. Statistical analysis of data was made

The paper explained

Problem

Since December 2019, COVID-19 has widely spread throughout the world, causing more than one million of deaths. Although clinical characteristics of COVID-19 patients have been widely reported, significant disease-associated biomarkers remain unknown. We evaluated the potential of circulating sphingosine-1-phosphate (S1P) as a prognostic and predictive biomarker in COVID-19.

Results

We report demographic, clinical, and laboratory findings of 111 patients with COVID-19, compared to 47 healthy subjects. Several blood parameters, including erythrocyte and lymphocyte number, neutrophil-to-lymphocyte ratio, and biochemical variables encompassing albumin, ferritin, D-dimer, and fibrinogen were found different in COVID-19. The novel, major finding of this work was the significant decrease of serum S1P level in COVID-19 patients, which was significantly related to the decrease of erythrocytes, the major cellular source of circulating S1P, as well as of the two key S1P transporters apoM and albumin. Of relevance, the serum levels of S1P, RBCs, apoM, and albumin exhibited the lowest values in patients admitted to intensive care unit (ICU). Multivariate logistic regression analyses revealed that S1P was the only parameter significantly associated with ICU admission, as well as the strongest predictor for both ICU admission and mortality risk.

Impact

The results of this study establish S1P as a novel circulating biomarker negatively associated with COVID-19 severity and morbidity, and shed light on the pathophysiology of the disease. Interventions to restore S1P abnormal levels should be considered as a potential therapeutic strategy for reducing the hazard of disease progression and death, and for mounting an effective immune response in patients with COVID-19.
using IBM SPSS Statistics 26.0 software. Data acquisition was performed blindly. The tests were all two-sided and were considered statistically significant when \( P < 0.05 \). In all cases, we report exact \( P \) value of the analyzed data, except when \( P < 0.0001 \), reported as such, as it is widely recognized as highly statistically significant.

Data availability

The data used to support the findings of this study are available from the corresponding author upon request.

Acknowledgments

This work was supported by Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico (RC2020 to GM). The present study was born thanks to the collaboration between civil and military health system, such as the Italian Air Force Medical Corps, which actively participated in management of COVID-19 outbreak during the most critical phases of the emergency in Lombardy and throughout Italy. The work was also arranged thanks to the Framework Agreement between the IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Italian Air Force, and University of Milan. We apologize for not mentioning all the relevant articles pertinent to our study, due to limit of references. We thank all patients and their family members and all the frontline health workers for their efforts in the diagnosis and treatment of patients during COVID-19 pandemic.

Author contributions

GM, SN, LG, and LR had the idea for and designed the study. GM, SN, LG, MMo, MMi, SC, and LR collected the epidemiological, clinical data and were involved in data interpretation. SN and LG performed ELISA assay and processed statistical data. MG, SN, LG, and LR wrote the manuscript. All the authors critically revised the manuscript for intellectual content.

Conflict of interest

The authors declare that they have no conflict of interest.

References

Abdel Hadi L, Anelli V, Guarnaccia L, Navone S, Beretta M, Moccia F, Tringali C, Urechio V, Campanella R, Marfia G et al (2018) A bidirectional crosstalk between glioblastoma and brain endothelial cells potentiates the angiogenic and proliferative signaling of sphingosine-1-phosphate in the glioblastoma microenvironment. Biochim Biophys Acta Mol Cell Biol Lipids 1863: 1179 – 1192

Baeyens AAL, Schwab SR (2020) Finding a way out: SIP signaling and immune cell migration. Annu Rev Immunol 38: 759 – 784

Becker S, Kinny-Köster B, Bartels M, Scholz M, Seehofer D, Berg T, Engellmann C, Thierry J, Ceglarek U, Kaiser T (2017) Low sphingosine-1-phosphate plasma levels are predictive for increased mortality in patients with liver cirrhosis. PLoS One 12: e0174424

Bryan AM, Del Poeta M (2018) Sphingosine-1-phosphate receptors and innate immunity. Cell Microbiol 20: e12836

Che W, Parmentier J, Seidel P, Manetsch M, Ramsay EE, Alkhouri H, Ge Q, Armour CL, Ammit AJ (2014) Corticosteroids inhibit sphingosine 1-phosphate-induced interleukin-6 secretion from human airway smooth muscle via mitogen-activated protein kinase phosphatase 1-mediated repression of mitogen and stress-activated protein kinase 1. Am J Respir Cell Mol Biol 50: 358 – 368

Christensen PM, Bosteen MH, Hajny S, Nielsen LB, Christoffersen C (2017) Apolipoprotein M mediates sphingosine-1-phosphate efflux from erythrocytes. Sci Rep 7: 14983

Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahsnstrom J, Sevanna M, Egerer-Sieber C, Muller YA, Hia T, Nielsen LB et al (2011) Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA 108: 9613 – 9618

Ciccullo A, Borghetti A, Zileri Dal Verme L, Tosoni A, Lombardi F, Garovich M, Biscetti F, Montalto M, Cauda R, Di Giambenedetto S et al (2020) Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line. Int J Antimicrob Agents 56: 106017

Daum G, Winkler M, Moritz E, Müller T, Geffenken M, von Lucadou M, Haddad M, Peine S, Böger RH, Larena-Avellaneda A et al (2020) Determinants of serum- and plasma sphingosine-1-phosphate concentrations in a healthy study group. Th Open 4: e12 – e19

Edsal L, Vann L, Milstien S, Spiegel S (2000) Enzymatic method for measurement of sphingosine 1-phosphate. Methods Enzymol 312: 9 – 16

Feingold KR, Shigenaga JK, Chui LG, Moser A, Khovdunkunt W, Grunfeld C (2008) Infection and inflammation decrease apolipoprotein M expression. Atherosclerosis 16: 19 – 26

Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D (2020) COVID-19 does not lead to a “typical” acute respiratory distress syndrome. Am J Respir Crit Care Med 201: 1299 – 1300

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC et al (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 382: 1708 – 1720

Hänel P, Andréani P, Gräpler MH (2007) Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J 21: 1202 – 1209

Jeya Paul J, Weigel C, Meller S, Fehmers A, Veldhuizen W (2017) Determinants of sphingosine 1-phosphate stored in human erythrocytes. Blood 129: 2107 – 2117

Jeya Paul J, Weigel C, Meller S, Fehmers A, Veldhuizen W (2017) Determinants of sphingosine 1-phosphate stored in human erythrocytes. Blood 129: 2107 – 2117

Jeya Paul J, Weigel C, Meller S, Fehmers A, Veldhuizen W (2017) Determinants of sphingosine 1-phosphate stored in human erythrocytes. Blood 129: 2107 – 2117

Kurano M, Yatomi Y (2018) Sphingosine 1-phosphate and atherosclerosis. J Atheroscler Thromb 25: 16 – 26

Ledford H (2020) Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature 582: 469

Liu X, Zhang QH, Yi GH (2012) Regulation of metabolism and transport of sphingosine-1-phosphate in mammalian cells. Mol Cell Biochem 363: 21 – 33

Nagahashi M, Kim EY, Yamada A, Ramachandran S, Allegood JC, Hait NC, Maceyka M, Milstien S, Takabe K, Spiegel S (2013) Smn2, a transporter of phosphorylated sphingoid bases, regulates their blood and lymph levels, and the lymphatic network. FASEB J 27: 1001 – 1011

Obinata H, Hia T (2019) Sphingosine 1-phosphate and inflammation. Int Immunol 31: 617 – 625

Ohkawa R, Nakamura K, Okubo S, Hosogaya S, Ozaki Y, Tozuka M, Oshima N, Yokota H, Ikeda H, Yatomi Y (2008) Plasma sphingosine-1-phosphate measurement in healthy subjects: close correlation with red blood cell parameters. Ann Clin Biochem 45: 356 – 363

Oldstone MB, Rosen H (2014) Cytokine storm plays a direct role in the morbidity and mortality from influenza virus infection and is chemically treatable with a single sphingosine-1-phosphate agonist molecule. Curr Top Microbiol Immunol 378: 129 – 147
Pelletier D, Hafler DA (2012) Fingolimod for multiple sclerosis. *N Engl J Med* 366: 339 – 347

Pierce CN, Larson DF (2005) Inflammatory cytokine inhibition of erythropoiesis in patients implanted with a mechanical circulatory assist device. *Perfusion* 20: 83 – 90

Satci C, Demirkol MA, Sargin Altunok E, Gursoy B, Alkan M, Kamat S, Demirok B, Surmeli CD, Calik M, Cavus Z et al (2020) Performance of pneumonia severity index and CURB-65 in predicting 30-day mortality in patients with COVID-19. *Int J Infect Dis* 98: 84 – 89

Sotgiu G, Gerli AG, Centanni S, Miozzo M, Canonica GW, Soriano JB, Virchow JC (2020) Advanced forecasting of SARS-CoV-2-related deaths in Italy, Germany, Spain, and New York State. *Allergy* 75: 1813 – 1815

Streetz KL, Wustefeld T, Klein C, Manns MP, Trautwein C (2001) Mediators of inflammation and acute phase response in the liver. *Cell Mol Biol* 47: 661 – 673

Thomas T, Stefanoni D, Dzieciatkowska M, Issaian A, Nemkov T, Hill RC, Francis RO, Hudson KE, Buehler PW, Zimring JC et al (2020) Evidence for structural protein damage and membrane lipid remodeling in red blood cells from COVID-19 patients. medRxiv https://doi.org/10.1101/2020.06.29.20142703 [PREPRINT]